Silodosin in Management of Lower Ureteral Stones

The Use of Selective Alpha Blockers (Silodosin) in Management of Lower Ureteral Stones Larger Than 6 mm in Diameter

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06381206

Enrollment

100

Registered

2024-04-24

Start date

2022-10-20

Completion date

2023-10-25

Last updated

2024-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stone, Kidney

Keywords

Silodosin, Lower Ureteral, Ureteral Stones

Brief summary

This research aims to study the effectiveness of silodosin in the management of lower ureter stones larger than 6 mm in diameter in terms of affected ureter (right or left), the size of the stone, the degree of hydronephrosis, the rate of stone expulsion(day), whether the stone was completely expelled or not, and the side effects of silodosin.

Interventions

DRUGSilodosin

Selective Alpha Blocker drug

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients attending the urology Clinic with a distal unilateral ureteral stone larger than 6 mm in diameter.

Exclusion criteria

* Patients under 18 years of age * Pregnant women * Patients with whom we were unable to contact * Patients treated with silodosin for another reason * Single kidney patients * Patients with bilateral ureter stones * Patients with deteriorating kidney function * Patients with grades 3rd and 4th of hydronephrosis

Design outcomes

Primary

Measure	Time frame	Description
Stone expulsion (yes)	1 year	patients who were able to expel the stone
Stone expulsion (no)	1 year	patients who were not able to expel the stone

Countries

Syria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026